Compare Mesoblast Limited (MESO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Omnicom Group Inc. — how do they compare? Mesoblast Limited trades at $14.26 (market cap $1.75B), while Omnicom Group Inc. trades at $76.39 (market cap $20.97B). The key difference: Omnicom Group Inc. is far larger — about 12× Mesoblast Limited's market cap, and Omnicom Group Inc. pays a 4.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Omnicom Group Inc. for 63 Days on average.
| MESO | OMC | |
|---|---|---|
Market Cap | $1.75B | $20.97B |
Volume | 239,027 | 2,092,899 |
Sector | Health | Media |
52-Week High | $20.96 | $88.94 |
52-Week Low | $13.19 | $67.27 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | $1.83B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.5M. Recent business developments include significant new billings of $3.3B in H1 2026 and leadership recognition in Gartner reports. Analyst consensus is mixed with 32% buy ratings but a $100.50 price target suggesting 34% upside potential.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.86) and dividend yield, though recent earnings misses and high P/E ratio of 206.62 raise concerns. Key risks include advertising market volatility and debt levels, while catalysts include AI integration and post-merger synergies from the Interpublic acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
